Activation of the Metabolic Master Regulator PPARγ: A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.

摘要: Translational research is essential to the development of reverse-remodeling strategies for treatment pulmonary vascular disease, hypertension, and heart failure via mechanistic in vivo studies using animal models resembling human arterial hypertension (PAH), cardiovascular remodeling, progressive right failure. Since 2007, peroxisome proliferator-activated receptor γ (PPARγ) agonists have emerged as promising novel, antiproliferative, antiinflammatory, insulin-sensitizing, efficient medications PAH. However, early diabetes study results, their subsequent misinterpretations, errors published review articles, rumors regarding potential adverse effects literature dampened enthusiasm considering pharmacological PPARγ activation diseases, including Most recently, thiazolidinedione class agonist pioglitazone underwent a clinical revival, especially based on IRIS (Insulin Resistance Intervention After Stroke) study, randomized controlled trial 3,876 patients without status post-transient ischemic attack/ischemic stroke who were clinically followed 4.8 years. We discuss preclinical basic translational findings trials related beneficial class, with particular focus last 5 The objective data-driven approach set record straight. convincing recent data lack significant toxicity high-risk populations justify timely conduct achieve "repurposing" or "repositioning"